

# Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea

**Hee Kyung Kim, MD<sup>1</sup>, Jun Soo Ham, MD<sup>1</sup>, Seonggyu Byeon, MD<sup>1</sup>, Kwai Han Yoo, MD<sup>1</sup>, Ki Sun Jung, MD<sup>1</sup>, Haa-Na Song, MD<sup>1</sup>, Jinhyun Cho, MD<sup>1</sup>, Ji Yun Lee, MD<sup>1</sup>, Sung Hee Lim, MD<sup>1</sup>, Hae Su Kim, MD<sup>1</sup>, Ji-Yeon Kim, MD<sup>1</sup>, Jeong Eon Lee, MD, PhD<sup>2</sup>, Seok Won Kim, MD, PhD<sup>2</sup>, Seok Jin Nam, MD, PhD<sup>2</sup>, Se Kyung Lee, MD, PhD<sup>2</sup>, Soo Youn Bae, MD, PhD<sup>2</sup>, Jin Seok Ahn, MD, PhD<sup>1</sup>, Young-Hyuck Im, MD, PhD<sup>1</sup>, Yeon Hee Park, MD, PhD<sup>1</sup>**

<sup>1</sup>*Division of Hematology-Oncology, Department of Internal Medicine,*

<sup>2</sup>*Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea*

## Supplementary Data

### Table of Contents

Supplementary Table 1 .....	2
Supplementary Table 2 .....	3

**Supplementary Table 1.** Univariate analysis for RFSR

Variable	Age < 65 yr		Age ≥ 65 yr	
	5-Yr RFSR (95% CI, %)	p-value	5-Yr RFSR (95% CI, %)	p-value
<b>TNM stage at diagnosis</b>				
I	93.3 (92.1-94.5)	< 0.001	88.4 (82.5-94.3)	< 0.001
II	89.3 (87.9-90.7)		84.8 (78.8-90.9)	
III	69.5 (65.9-73.0)		69.4 (56.1-82.7)	
<b>Subtypes</b>				
HR(+)/HER2(-)	90.9 (89.7-92.1)	< 0.001	88.4 (82.5-94.3)	0.159
HR(+)/HER2(+)	81.9 (77.9-85.8)		84.0 (69.7-98.3)	
HR(-)/HER2(+)	81.6 (78.1-85.1)		88.8 (78.4-99.2)	
TNBC	84.2 (81.4-86.9)		76.7 (65.9-87.5)	
<b>Nuclear grade</b>				
I	95.5 (93.7-97.3)	< 0.001	91.3 (83.1-99.5)	0.006
II	88.8 (87.2-90.4)		86.9 (80.8-92.9)	
III	83.8 (82.0-85.6)		76.2 (68.4-84.0)	
<b>Histologic grade</b>				
Low	96.9 (95.5-98.3)	< 0.001	92.6 (85.5-99.7)	0.034
Intermediate	88.8 (87.2-90.4)		83.2 (76.3-90.1)	
High	81.5 (79.5-83.5)		79.3 (71.1-87.5)	
<b>Ki-67 (%)</b>				
< 50	92.8 (91.4-94.2)	< 0.001	85.1 (78.6-91.6)	0.425
≥ 50	83.8 (80.9-86.7)		82.3 (72.3-92.3)	
<b>Lymphovascular invasion</b>				
Yes	87.7 (83.8-91.6)	< 0.001	52.3 (28.2-76.4)	0.001
No	95.9 (94.3-94.5)		91.6 (84.5-98.7)	
<b>Adjuvant chemotherapy</b>				
Yes	86.8 (85.6-87.9)	< 0.001	83.3 (77.2-89.4)	0.293
No	91.4 (89.4-93.4)		84.4 (78.3-90.5)	
<b>Adjuvant radiotherapy</b>				
Yes	88.0 (86.8-89.2)	0.425	84.7 (78.8-90.6)	0.83
No	86.9 (84.9-88.9)		83.0 (76.9-89.1)	
<b>Adjuvant endocrine therapy</b>				
Yes	90.0 (88.8-91.2)	< 0.001	86.2 (80.9-91.5)	0.387
No	83.1 (81.1-85.1)		80.5 (73.2-87.8)	

RFSR, recurrence-free survival rate; CI, confidence interval; HR, hormone receptor; TNBC, triple negative breast cancer.

**Supplementary Table 2.** Univariate analysis for OSR

Variable	Age < 65 yr		Age ≥ 65 yr	
	5-Yr OSR (95% CI, %)	p-value	5-Yr OSR (95% CI, %)	p-value
<b>TNM stage at diagnosis</b>				
I	98.1 (97.5-98.7)	< 0.001	94.7 (90.6-98.5)	< 0.001
II	95.0 (94.1-96.1)		91.8 (87.1-96.5)	
III	83.1 (80.2-86.1)		83.5 (72.1-94.9)	
<b>Subtypes</b>				
HR(+)/HER2(-)	97.1 (96.5-97.7)	< 0.001	92.4 (88.5-96.3)	0.489
HR(+)/HER2(+)	93.0 (90.5-95.5)		100	
HR(-)/HER2(+)	90.2 (87.5-92.9)		88.4 (77.6-99.2)	
TNBC	88.7 (86.3-91.1)		88.0 (79.6-96.4)	
<b>Nuclear grade</b>				
I	99.6 (99.0-100)	< 0.001	95.8 (90.1-100)	0.322
II	95.3 (94.3-96.3)		92.7 (88.2-97.2)	
III	91.4 (90.0-92.8)		88.0 (81.9-94.1)	
<b>Histologic grade</b>				
Low	99.4(98.8-99.9)	< 0.001	98.1 (94.6-100)	0.019
Intermediate	95.7 (94.7-96.7)		93.1 (88.4-97.8)	
High	89.7 (88.1-91.3)		87.2 (80.5-93.9)	
<b>Ki-67 (%)</b>				
< 50	97.2 (96.4-97.9)	< 0.001	92.3 (87.4-97.4)	0.575
≥ 50	90.9 (88.5-93.3)		90.9 (83.3-98.5)	
<b>Lymphovascular invasion</b>				
Yes	94.3 (91.6-97.0)	< 0.001	78.3 (56.5-100)	< 0.001
No	98.8 (97.8-99.8)		93.4 (87.1-99.7)	
<b>Adjuvant chemotherapy</b>				
Yes	94.0 (93.2-94.8)	0.003	93.6 (89.5-97.7)	0.824
No	95.2 (93.6-96.8)		90.0 (85.3-94.7)	
<b>Adjuvant radiotherapy</b>				
Yes	94.7 (93.9-95.5)	0.055	93.8 (93.4-94.2)	0.135
No	93.1 (91.7-94.5)		89.7 (84.8-94.6)	
<b>Adjuvant endocrine therapy</b>				
Yes	97.4 (96.8-97.9)	< 0.001	94.9 (91.6-98.2)	0.038
No	88.0 (86.2-89.8)		86.9 (80.6-93.2)	

OSR, overall survival rate; CI, confidence interval; HR, hormone receptor; TNBC, triple negative breast cancer.